- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00429897
Double Blind Crossover Comparison of Diuretics in the Young
Double Blind Crossover Comparison od Diuretics in Young Patients With Low Renin Hypertension
The principle objective of the study is to determine whether low-renin (i.e. salt sensitive) hypertension at a young age is caused by the kidneys hanging onto too much salt as a result of an over active salt pump in the kidney.
The kidneys have four different salt pumps, and each is blocked by a different type of diuretic (salt losing tablet)If one out of the four is overactive, we would expect patients to respond much better to one diuretic than to the alternatives - rather than responding equally well to all available types of diuretic.
Study Overview
Status
Conditions
Detailed Description
Studies suggest that patients with low renin hypertension respond better to diuretics than other hypertensive drug groups. The aim of the study is to rotate patients through the four main diuretic groups and see if it is possible to identify the most effective diuretic for this group, as measured by a >=10mgHg decrease in Systolic blood pressure in one specific group a compared to the others.
As most caucasians with Low renin hypertension are older (>55), presentation with this type of hypertension at a younger age suggests the presence of substantial genetic variation in order to cause the atypical presentation. It is hoped that by identifying the best diuretic for these patients we will also be able to identify:
- Whether the young low-renin hypertensives can be sub-classified according to their most effective diuretic;
- Whether this sub-classification helps us to identify the genes and mutations responsible, since these are to expected to be in the so-called sodium channels (i.e. salt pumps)which the kidneys use to prevent salt being excreted in the urine.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Morris J Brown, Professor
- Phone Number: 01223 336743
- Email: mjb14@medschl.cam.ac.uk
Study Locations
-
-
-
Cambridge, United Kingdom, CB2 2QQ
- Recruiting
- University of Cambridge - Addenbrookes Hospital
-
Contact:
- Morris J Brown, Proffessor
- Phone Number: 01223 336743
- Email: mjb14@medschl.cam.uk
-
Sub-Investigator:
- Sue Hood, RGN - sister
-
Sub-Investigator:
- Diane Picton, RGN- sister
-
Sub-Investigator:
- Tim Burton, Phd, MRCP
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-45
- male or female
- Hypertensive - 3 clinic SBP >=140mmHg; or 3 clinic DBP >=90mmHg; or ABPM or home BP >=130(SBP) or 85(DBP)
- 24hr Na+<160mmol/l
- EITHER {Plasma renin<=10mU/L (measured untreated, or whilst receiving only CCB+/-diuretic} + {Plasma renin <=40mU/L (measured on an ACEi or ARB, which approximately double s the plasma renin)} OR Plasma renin <5mU/L (measured untreated, or receiving any antihypertensive drug other than a beta-blocker
Exclusion Criteria:
- Documented history of gout
- Abnormal renal function (both elevated serum creatinine and reduced creatinine clearance
- SBP > 170mmHg or Diastolic >110mmHg despite treatment with permitted background treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Difference in systolic blood pressure for subjects' best drug and second best drug.
|
Difference in plasma renin for subjects' best drug and second best drug.
|
Secondary Outcome Measures
Outcome Measure |
---|
Predictions of best drug
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Morris J Brown, Proffessor, Cambridge University
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium Channel Blockers
- Hormone Antagonists
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Sodium Chloride Symporter Inhibitors
- Sodium Potassium Chloride Symporter Inhibitors
- Acid Sensing Ion Channel Blockers
- Epithelial Sodium Channel Blockers
- Spironolactone
- Furosemide
- Bendroflumethiazide
- Amiloride
Other Study ID Numbers
- 1.0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low-Renin Hypertension
-
University of North Carolina, Chapel HillWake Forest University Health Sciences; Cornell UniversityCompletedHypertension | Plasma Renin ActivityUnited States
-
Rennes University HospitalTerminated
-
University of EdinburghCompletedRenin Angiotensin SystemUnited Kingdom
-
North-West University, South AfricaGlaxoSmithKline; Novartis; Pfizer; Boehringer Ingelheim; Medical Research Council; Medical... and other collaboratorsActive, not recruitingCardiovascular Diseases | Hypertension | Health Risk Behaviors | Arterial Stiffness | Young | Renin HypertensionSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedSurgery | Renin Angiotensin SystemFrance
-
University Children's Hospital BaselCompletedRenin-Angiotensin Aldosterone System (RAS)Switzerland
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone SystemUnited States
-
Seoul National University Bundang HospitalCompletedHypertension | Diabetes Mellitus, Type 2 | Angiotensin/Renin/Aldosterone HypertensionKorea, Republic of
-
Göteborg UniversitySahlgrenska University Hospital, SwedenCompletedthe Local Renin-angiotensin System (RAS) in Small Intestinal Mucosa in ManSweden
-
Ain Shams UniversityCompleted
Clinical Trials on Bendroflumethiazide 2.5mg - 5mg
-
Vigonvita Life SciencesCompletedErectile DysfunctionChina
-
Vigonvita Life SciencesCompleted
-
Suzhou Kintor Pharmaceutical Inc,CompletedTo Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic AlopeciaAlopecia | Male Pattern Hair LossUnited States
-
BayerCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHypertension | HypercholesterolemiaJapan
-
Dong-A ST Co., Ltd.Completed
-
PfizerCompletedOsteoarthritis, Knee | Osteoarthritis, HipUnited States, Puerto Rico, Canada
-
Dong-A ST Co., Ltd.Active, not recruitingOveractive BladderKorea, Republic of
-
Dong-A ST Co., Ltd.CompletedOveractive BladderKorea, Republic of